Book contents
- Frontmatter
- Contents
- List of contributors
- Acknowledgements
- 1 Introduction
- Section I Information problems
- Section II End of life care
- Section III Pregnant women and children
- Section IV Genetics and biotechnology
- Section V Research ethics
- Introduction
- 25 Research ethics
- 26 Innovation in medical care: examples from surgery
- 27 Clinical trials
- 28 Epidemiological research
- 29 Clinical research and the physician–patient relationship: the dual roles of physician and researcher
- 30 Financial conflict of interest in medical research
- 31 Embryo and fetal research
- Section VI Health systems and institutions
- Section VII Using clinical ethics to make an impact in healthcare
- Section VIII Global health ethics
- Section IX Religious and cultural perspectives in bioethics
- Section X Specialty bioethics
- Index
- References
30 - Financial conflict of interest in medical research
Published online by Cambridge University Press: 30 October 2009
- Frontmatter
- Contents
- List of contributors
- Acknowledgements
- 1 Introduction
- Section I Information problems
- Section II End of life care
- Section III Pregnant women and children
- Section IV Genetics and biotechnology
- Section V Research ethics
- Introduction
- 25 Research ethics
- 26 Innovation in medical care: examples from surgery
- 27 Clinical trials
- 28 Epidemiological research
- 29 Clinical research and the physician–patient relationship: the dual roles of physician and researcher
- 30 Financial conflict of interest in medical research
- 31 Embryo and fetal research
- Section VI Health systems and institutions
- Section VII Using clinical ethics to make an impact in healthcare
- Section VIII Global health ethics
- Section IX Religious and cultural perspectives in bioethics
- Section X Specialty bioethics
- Index
- References
Summary
Dr. H is an expert on the treatment of depression. A pharmaceutical company, Calaxy Inc. signed a contract with Dr. H and his institution for a multisite three-year study on the efficacy and safety of a new antidepressant, Xanadu, for use in pregnant women. The contract stipulates that Dr. H will have access to all data for final analysis and that all publications based on the study will be submitted for final approval to the sponsor before public disclosure. Dr. H's budget includes money for finder's fees for clinicians who recruit patients into the trial and rewards for clinician–researchers whose patients remain in the trial for the duration of their pregnancy. In the course of the trial, Dr. H becomes worried about potential negative effects of Xanadu on newborns. He reveals his concern to the company, requests immediate access to all the data, and indicates that he will reveal his concerns at an upcoming international meeting. The company refers to a contradictory opinion of an internal data-monitoring committee set up by the sponsor, refuses to provide full access to the data, and points out that researchers have to obtain final approval of the sponsor before any public discussion of the results. Shortly after, Dr. H receives from Calaxy an abstract discussing the interim results of the study, accepted for presentation at an international conference. Dr. H is first author on the abstract, which does not contain any reference to his concerns. Dr. H contacts the chair of his department, Dr. I, who is a remunerated board member of Calaxy.[…]
- Type
- Chapter
- Information
- The Cambridge Textbook of Bioethics , pp. 222 - 230Publisher: Cambridge University PressPrint publication year: 2008
References
- 4
- Cited by